Associated Papers
Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study.
Sakaguchi H et al.
Esmo Open, 2025
Emerging genetic biomarkers in lung adenocarcinoma.
Barbar J et al.
Sage Open Medicine, 2022
NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E et al.
Molecular Oncology, 2021
34058070 (PubMed )
Supplement: MOL2-15-2363-s001.docx
Resistance to molecularly targeted therapy in non-small-cell lung cancer.
Asao T et al.
Respiratory Investigation, 2019
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
Katayama R et al.
Science Translational Medicine, 2012
Select a paper to view details